オプションチェーンは、Cardio Diagnostics Hldgsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Cardio Diagnostics Hldgsの市場センチメントを評価します。.

Cardio Diagnostics Hldgs (NASDAQ:CDIO) 株価情報, オプションチェーン

Cardio Diagnostics Hldgs

Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Holdings Inc

Cardio Diagnostics Holdings Inc. - Warrant

BrainsWay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWAY#NASDAQ">BWAY</a>) affirms FY2025 sales outlook from $49.00 million-$51.00 million to $49.00 million-$51.00 million vs $179.75 million estimate.

News

Guidance

BWAY

BrainsWay Affirms FY2025 Sales Guidance of $49.00M-$51.00M vs $179.75M Est

Intuitive Machines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) affirms FY2025 sales outlook from $250.00 million-$300.00 million to $250.00 million-$300.00 million vs $272.53 million estimate.

LUNR

Intuitive Machines Affirms FY2025 Sales Guidance of $250.00M-$300.00M vs $272.53M Est

BrainsWay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWAY#NASDAQ">BWAY</a>) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.09 by 77.78 percent. The company reported quarterly sales of $11.54 million which missed the analyst consensus estimate of $41.39 million by 72.13 percent. This is a 26.84 percent increase over sales of $9.10 million the same period last year.

Earnings

Earnings Misses

BrainsWay Q1 EPS $0.02 Misses $0.09 Estimate, Sales $11.54M Miss $41.39M Estimate

NeuroOne Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) reported quarterly losses of $(0.07) per share. This is a 36.36 percent increase over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $1.39 million which beat the analyst consensus estimate of $1.27 million by 9.18 percent. This is a 0.69 percent increase over sales of $1.38 million the same period last year.

Earnings Beats

NMTC

NeuroOne Medical Tech Q2 EPS $(0.07) Up From $(0.11) YoY, Sales $1.39M Beat $1.27M Estimate

Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.15) by 13.33 percent. This is unchanged from the same period last year.

AVXL

Anavex Life Sciences Q2 EPS $(0.13) Beats $(0.15) Estimate

Achieve Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHV#NASDAQ">ACHV</a>) reported quarterly losses of $(0.37) per share which met the analyst consensus estimate. This is a 42.31 percent decrease over losses of $(0.26) per share from the same period last year.

ACHV

Achieve Life Sciences Q1 EPS $(0.37), Inline

Alzamend Neuro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) on Tuesday announced the initiation of the first of five Phase 2 clinical studies of AL001, with the first study in <a target="_blank" href="https://www.benzinga.com/exclusives" rel="noreferrer noopener">healthy human subjects</a>.
This study follows the development of a novel head coil by Tesla Dynamic Coils BV, a key <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43809487/exclusive-alzamend-neuro-says-tesla-dynamic-completes-head-coil-to-measure-brain-structure-lithium-levels" rel="noreferrer noopener">component of the clinical trial</a>.
In collaboration with Massachusetts General Hospital as its clinical trial site, Alzamend aims to explore AL001 and its potential to deliver lithium more effectively in the brain than <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43937141/exclusive-alzamend-neuro-to-start-first-phase-2-study-for-lead-candidate-in-2025" rel="noreferrer noopener">marketed lithium salts</a>.
The study in healthy human subjects will serve as a baseline and assist Alzamend to determine the best path forward in Alzheimer's, bipolar disorder, major depressive disorder, and post-traumatic stress disorder patients by demonstrating AL001's targeted effectiveness and reduced systemic side effects.
Topline data is expected by the end of 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45249094/exclusive-alzamend-neuro-partners-with-qmenta-to-advance-ai-powered-imaging-for-is-phase-2-trial-of-lead-program" rel="noreferrer noopener">EXCLUSIVE: Alzamend Neuro Partners with QMENTA To Advance AI-Powered Imaging For Is Phase 2 Trial Of Lead Program</a>
Previous studies in mice have shown that AL001 ensures better brain absorption while maintaining lower levels of lithium in the blood, paving the way for safer and more efficient treatments.
In March, Alzamend Neuro&nbsp;announced its plans to initiate a phase 2 clinical study of AL001 for patients with post-traumatic stress disorder in the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44243481/exclusive-alzamend-neuro-to-launch-phase-2-study-for-lead-drug-for-ptsd-patients-in-late-2025-to-assess-lithium-delivery-benefits" rel="noreferrer noopener">fourth quarter of 2025</a>.
In November 2024, Alzamend Neuro finished analyzing a nonclinical study's final full data set comparing brain and plasma lithium exposures between AL001 and lithium carbonate in <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42059707/exclusive-alzamend-neuro-reveals-full-data-from-nonclinical-study-of-its-lead-alzheimers-drug-potential" rel="noreferrer noopener">Alzheimer's transgenic mice</a>.
The study involved administering AL001 to 5XFAD mice, a recognized model for Alzheimer's research, to compare its effects against lithium carbonate, an FDA-approved and marketed API.
Mice received high or low doses, scaled to humans, of AL001 and lithium carbonate over 14 days to observe pharmacokinetic steady-state drug conditions.
Last week, the company's board of directors approved a one-for-nine reverse stock split of its common stock to maintain compliance with the minimum bid price requirement of $1.00 per share required to maintain continued listing on the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45282840/alzamend-neuro-announces-reverse-stock-split" rel="noreferrer noopener">Nasdaq Capital Market</a>.
Price Action: At the last check on Tuesday, ALZN stock was up 6.57% to $5.49 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45358050/nano-cap-neurosense-therapeutics-gets-14-price-forecast-as-primec-nears-key-als-milestones" target="_blank" rel="noreferrer noopener">Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights</a></li>
</ul>

Biotech

Health Care

Market-Moving Exclusives

Exclusives

General

ALZN

EXCLUSIVE: Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human Participants

EXLCUSIVE: Alzamend Neuro Tells Benzinga 'Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects'

EXLCUSIVE: Alzamend Neuro Tells Benzinga 'Topline data expected by year end'

EXLCUSIVE: Alzamend Neuro Tells Benzinga Co. Initiates First Phase II Clinical Trial Of AL001 Lithium Brain Study Taking Place At Massachusetts General Hospital

Canaccord Genuity analyst Joseph Vafi maintains BILL Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>) with a Buy and lowers the price target from $105 to $75.

Price Target

Analyst Ratings

BILL

Canaccord Genuity Maintains Buy on BILL Holdings, Lowers Price Target to $75

Chardan Capital analyst Geulah Livshits maintains Lexeo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEO#NASDAQ">LXEO</a>) with a Buy and lowers the price target from $22 to $20.

LXEO

Chardan Capital Maintains Buy on Lexeo Therapeutics, Lowers Price Target to $20

Needham analyst Joshua Reilly reiterates ZoomInfo Technologies Inc. - Common Stock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTM#NASDAQ">GTM</a>) with a Buy and maintains $15 price target.

Reiteration

Needham Reiterates Buy on ZoomInfo Technologies Inc. - Common Stock, Maintains $15 Price Target

WIIM

CYBR

CyberArk Software shares are trading lower. The company reported Q1 financial results.

The most oversold stocks in the information technology sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">CPI Card Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMTS#NASDAQ">PMTS</a>)</h3>
<ul class="wp-block-list">
<li>On May 7, CPI Card reported worse-than-expected first-quarter earnings. &#8220;We are pleased with our first quarter sales performance, led by strong growth from our debit and credit card portfolio,&#8221; said John Lowe, President and Chief Executive Officer. &#8220;Our outlook remains intact, and we plan to continue to execute our strategies to gain share and diversify our business, as evidenced by our acquisition of Arroweye Solutions.&#8221; The company's stock fell around 22% over the past five days and has a 52-week low of $18.46.</li>
<li>RSI Value: 29.4</li>
<li>PMTS Price Action: Shares of CPI Card fell 4.8% to close at $20.48 on Monday.</li>
<li>Edge Stock Ratings: 26.27 Momentum score with Value at 43.86. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/PMTS"><img loading="lazy" decoding="async" width="470" height="172" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13042818/image-134.png" alt="" class="wp-image-913102" style="width:372px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13042818/image-134.png 470w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13042818/image-134-300x110.png 300w" sizes="(max-width: 470px) 100vw, 470px" /></a></figure>
<h3 class="wp-block-heading">Astrotech Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTC#NASDAQ">ASTC</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul class="wp-block-list">
<li>On Feb. 14, Astrotech reported its financial results for the second quarter of fiscal year 2025, which ended Dec. 31, 2024. Thomas B. Pickens, III, Astrotech&#8217;s Chairman, Chief Executive Officer and Chief Technology Officer, said &#8220;We are now prioritizing and accelerating our attention to selling and marketing our line of portable, rugged and inexpensive mass spectrometry instruments. We believe 1st Detect&#8217;s explosive trace detection products are now proven with four years of use in cargo warehouses having run thousands of samples at airports in 14 countries.&#8221; The company's stock fell around 16% over the past six months and <a href="https://www.benzinga.com/quote/ASTC">has a 52-week low</a> of $5.72.</li>
<li>RSI Value: 26.1</li>
<li>ASTC Price Action: Shares of Astrotech gained 2.3% to close at $5.90 on Monday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0513">ASTC stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href=" https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0513"><img loading="lazy" decoding="async" width="922" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13042933/image-135.png" alt="" class="wp-image-913105" style="width:523px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13042933/image-135.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13042933/image-135-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13042933/image-135-768x701.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<h3 class="wp-block-heading">reAlpha Tech Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>)</h3>
<ul class="wp-block-list">
<li>On April 28, reAlpha Tech announced the appointment of Cristol Rippe as Chief Marketing Officer. &#8220;Cristol&#8217;s arrival marks an exciting new chapter for the reAlpha executive team,&#8221; said Mike Logozzo, President and Chief Operating Officer of reAlpha. The company's stock fell around 16% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/AIRE">low of $0.51.</a></li>
<li>RSI Value: 29.2</li>
<li>AIRE Price Action: Shares of reAlpha Tech fell 0.1% to close at $0.58 on Monday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0513">AIRE shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href=" https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0513"><img loading="lazy" decoding="async" width="868" height="821" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13043038/image-136.png" alt="" class="wp-image-913108" style="width:616px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13043038/image-136.png 868w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13043038/image-136-300x284.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13043038/image-136-768x726.png 768w" sizes="(max-width: 868px) 100vw, 868px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> 
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/news/earnings/25/05/45368490/under-armour-cyberark-software-and-3-stocks-to-watch-heading-into-tuesday">Under Armour, CyberArk Software And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

AIRE

ASTC

PMTS

Top 3 Tech Stocks Which Could Rescue Your Portfolio This Quarter

Honda Motor shares are trading lower after the company reported a year-over-year decrease in FY25 GAAP EPS results.

ONON

On Holding shares are trading higher after the company reported better-than-expected Q1 financial results.

Immatics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMTX#NASDAQ">IMTX</a>) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.33) by 6.06 percent. This is a 713.95 percent decrease over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $19.54 million which beat the analyst consensus estimate of $15.42 million by 26.73 percent. This is a 40.56 percent decrease over sales of $32.87 million the same period last year.

IMTX

Immatics Q1 EPS $(0.35) Misses $(0.33) Estimate, Sales $19.54M Beat $15.42M Estimate

WestPark Capital analyst Casey Ryan reiterates Innoviz Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVZ#NASDAQ">INVZ</a>) with a Buy and maintains $2.22 price target.

INVZ

WestPark Capital Reiterates Buy on Innoviz Technologies, Maintains $2.22 Price Target

UnitedHealth Group shares are trading lower after the company announced it suspended its FY25 guidance. The company announced the appointment of Stephen Hemsley as CEO.

Press Releases

Cardio Diagnostics Holdings Inc. Launches CDIO.AI, A Redesigned Website Enhancing User Experience and Highlighting Our AI-Driven Cardiovascular Solutions

Potential Catalyst Right Around The Corner? CMS To Announce Preliminary Medicare Payment For Cardio Diagnostics' Heart Disease Tests

Cardio Diagnostics Holdings, Inc. Receives Preliminary Medicare Pricing from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests

Cardio Diagnostics Holdings, Inc. to Sponsor and Showcase AI-Powered Solutions at the FLAACOs Annual Conference

Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests

Trump's "Stargate AI" Healthcare/Medical Watch: CSDX, IPA, MGX, CDIO

Global Drug Screening Market Is Forecasted to Reach $19.5 Billion By 2029

Cardio Diagnostics Expands the Reach of its AI-Driven Precision Cardiovascular Medicine Tests by Partnering with Seven New Provider Organizations

Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD™, Actionable Clinical Intelligence™ and New Clinical Advancements at the American College of Cardiology's 74th Annual Scientific Session

Cardio Diagnostics Holdings, Inc. Announces 1-for-30 Reverse Stock Split

BIAF

CDIO

CSDX

INBS

SOBR

TRIB

Abeona Therapeutics

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Amarin Corporation plc - American Depositary Shares

Amarin Corp

Astria Therapeutics

Aura Biosciences

Candel Therapeutics

Cidara Therapeutics

Design Therapeutics

Foghorn Therapeutics

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Genfit

Gossamer Bio

Immutep Limited - American Depositary Shares

Immutep

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

ITeos Therapeutics

Kodiak Sciences

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Monopar Therapeutics

Neurogene

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Solid Biosciences

2seventy bio

Tevogen Bio Holdings

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals

Benchmark

Northland Capital Markets

Screenshot 2024-09-16 at 6.26.11 PM

Potential Catalyst Right Around The Corner? CMS To Announce Preliminary Medicare Payment For Cardio Diagnostics&#39; Heart Disease Tests

Screenshot 2024-05-23 at 10.15.30 PM

Interview

This Medtech Company Is Bringing &#34;Precision&#34; Medicine To Cardiovascular Diagnostics

Screenshot 2024-05-06 at 5.31.30 PM

New Study Shows Cardio Diagnostics&#39; (NASDAQ: CDIO) PrecisionCHD Test Could Save Health Insurers Over $113 Million Annually

Screenshot 2024-04-30 at 5.36.02 PM

MRNA

3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation

Screenshot 2024-04-23 at 6.35.19 PM

As the Use of AI In Healthcare Grows, Cardio Diagnostic Is Using It In Quest to Help Prevent Cardiovascular Disease

Screenshot 2024-04-11 at 5.31.26 PM

Cardio Diagnostics Inks Groundbreaking Telehealth Agreement With Navierre And Expands Access To Cardiovascular Tests

Comments

Cardio Diagnostics Hldgs

Cardio Diagnostics Hldgs (CDIO) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル